Effects of Antioxidant Supplementation on Graves’ Disease: A Meta-Analysis
Objective. The main objective of this study is to evaluate the clinical efficacy of antithyroid drugs combined with antioxidant supplementation represented by selenium in the treatment of Graves’ disease. Methods. Relevant randomized controlled trials (RCTs) were searched in PubMed, MEDLINE, Embase,...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical pharmacy and therapeutics 2023-06, Vol.2023, p.1-11 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 11 |
|---|---|
| container_issue | |
| container_start_page | 1 |
| container_title | Journal of clinical pharmacy and therapeutics |
| container_volume | 2023 |
| creator | Song, Qi Ji, Xiaoxue Xie, Ying |
| description | Objective. The main objective of this study is to evaluate the clinical efficacy of antithyroid drugs combined with antioxidant supplementation represented by selenium in the treatment of Graves’ disease. Methods. Relevant randomized controlled trials (RCTs) were searched in PubMed, MEDLINE, Embase, the Cochrane Library databases, and the Chinese Medical Association. The search was conducted from the time of library construction to December 20, 2022. Three writers gradually examined, evaluated, and graded the literature and then used RevMan 5.3 to analyze the data and develop conclusions. Results. A total of seven papers were screened according to the search requirements. The results showed that free triiodothyronine (FT3) (WMD = −2.29, 95% CI: −3.55 to −1.02, P=0.0004), free thyroxine (FT4) (WMD = −0.62, 95% CI: −1.05 to −0.18, P=0.0005), thyrotropin receptor antibody (TRAb) (WMD = −1.31, 95% CI: −1.63 to −0.99, P |
| doi_str_mv | 10.1155/2023/5587361 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2824555815</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2824555815</sourcerecordid><originalsourceid>FETCH-LOGICAL-c257t-72097de9633ea17ac5212a13a7ed2671f02c40b86867f25622f887e2e95b90c93</originalsourceid><addsrcrecordid>eNp9kMFKAzEURYMoWKs7PyDgUscmL5Nkxt1QaxUqLtR1SGdeMKWdGSep2p2_4e_5JU5p18KDC4_D5XIIOefsmnMpR8BAjKTMtFD8gAy4UDIBzdkhGTBQeZJq0MfkJIQFY0xpEAMymziHZQy0cbSoo2--fGXrSJ_XbbvEFdbR9s-a9jft7AeG3-8feusD2oA3tKCPGG1S1Ha5CT6ckiNnlwHP9jkkr3eTl_F9MnuaPoyLWVKC1DHRwHJdYa6EQMu1LSVwsFxYjRUozR2DMmXzTGVKO5AKwGWZRsBcznNW5mJILna9bde8rzFEs2jWXT8iGMgglb0CLnvqakeVXRNCh860nV_ZbmM4M1tfZuvL7H31-OUOf_N1ZT_9__Qfouxo_Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2824555815</pqid></control><display><type>article</type><title>Effects of Antioxidant Supplementation on Graves’ Disease: A Meta-Analysis</title><source>ProQuest Central (Alumni Edition)</source><source>Wiley Online Library Open Access</source><source>ProQuest Central UK/Ireland</source><source>Alma/SFX Local Collection</source><source>ProQuest Central</source><creator>Song, Qi ; Ji, Xiaoxue ; Xie, Ying</creator><contributor>Hosohata, Keiko ; Keiko Hosohata</contributor><creatorcontrib>Song, Qi ; Ji, Xiaoxue ; Xie, Ying ; Hosohata, Keiko ; Keiko Hosohata</creatorcontrib><description>Objective. The main objective of this study is to evaluate the clinical efficacy of antithyroid drugs combined with antioxidant supplementation represented by selenium in the treatment of Graves’ disease. Methods. Relevant randomized controlled trials (RCTs) were searched in PubMed, MEDLINE, Embase, the Cochrane Library databases, and the Chinese Medical Association. The search was conducted from the time of library construction to December 20, 2022. Three writers gradually examined, evaluated, and graded the literature and then used RevMan 5.3 to analyze the data and develop conclusions. Results. A total of seven papers were screened according to the search requirements. The results showed that free triiodothyronine (FT3) (WMD = −2.29, 95% CI: −3.55 to −1.02, P=0.0004), free thyroxine (FT4) (WMD = −0.62, 95% CI: −1.05 to −0.18, P=0.0005), thyrotropin receptor antibody (TRAb) (WMD = −1.31, 95% CI: −1.63 to −0.99, P<0.00001), and thyroid peroxidase antibody (TPOAb) (WMD = −9.8, 95% CI: −16.57 to −3.03, P=0.005) in the observation group (selenium supplementation combined with antithyroid drugs) were significantly lower than those in the control group (antithyroid drugs combined with or without placebo). In addition, selenium supplementation can increase serum selenium (WMD = 33.29, 95% CI: 30.7 to 35.87, P<0.00001), selenoprotein levels (WMD = 1.3, 95% CI: 0.8 to 1.8, P<0.00001), and blood lipid levels (WMD = 32.3, 95% CI: 17.87 to 46.74, P<0.0001). It cannot be excluded that the process of selenium supplementation treatment will affect the patient’s lipid levels. Conclusion. Selenium is a trace mineral that is crucial for human health. In patients with Graves’ disease, the use of antithyroid medications along with selenium supplementation can considerably enhance thyroid function. It has the potential to drastically lower TPOAb and TRAb levels as well as FT3 and FT4 levels, which is crucial for the treatment, recovery, and prognosis of hyperthyroid patients. Further research is required to determine whether the impact of antioxidant supplementation on blood lipids will restrict the use of this medication.</description><identifier>ISSN: 0269-4727</identifier><identifier>EISSN: 1365-2710</identifier><identifier>DOI: 10.1155/2023/5587361</identifier><language>eng</language><publisher>Oxford: Hindawi</publisher><subject>Antioxidants ; Clinical trials ; Drug dosages ; Enzymes ; Graves disease ; Hormones ; Hyperthyroidism ; Immune system ; Iodide peroxidase ; Lipids ; Medical research ; Meta-analysis ; Oxidative stress ; Patients ; Selenium ; Statistical analysis ; Supplements ; Thyroid ; Thyroid gland ; Thyroid hormones ; Thyroid-stimulating hormone ; Thyroxine ; Triiodothyronine</subject><ispartof>Journal of clinical pharmacy and therapeutics, 2023-06, Vol.2023, p.1-11</ispartof><rights>Copyright © 2023 Qi Song et al.</rights><rights>Copyright © 2023 Qi Song et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. https://creativecommons.org/licenses/by/4.0</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c257t-72097de9633ea17ac5212a13a7ed2671f02c40b86867f25622f887e2e95b90c93</cites><orcidid>0000-0002-0735-7198</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2824555815/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2824555815?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,21386,21387,27922,27923,33528,33742,43657,43803,64383,64387,72239,73874,74072</link.rule.ids></links><search><contributor>Hosohata, Keiko</contributor><contributor>Keiko Hosohata</contributor><creatorcontrib>Song, Qi</creatorcontrib><creatorcontrib>Ji, Xiaoxue</creatorcontrib><creatorcontrib>Xie, Ying</creatorcontrib><title>Effects of Antioxidant Supplementation on Graves’ Disease: A Meta-Analysis</title><title>Journal of clinical pharmacy and therapeutics</title><description>Objective. The main objective of this study is to evaluate the clinical efficacy of antithyroid drugs combined with antioxidant supplementation represented by selenium in the treatment of Graves’ disease. Methods. Relevant randomized controlled trials (RCTs) were searched in PubMed, MEDLINE, Embase, the Cochrane Library databases, and the Chinese Medical Association. The search was conducted from the time of library construction to December 20, 2022. Three writers gradually examined, evaluated, and graded the literature and then used RevMan 5.3 to analyze the data and develop conclusions. Results. A total of seven papers were screened according to the search requirements. The results showed that free triiodothyronine (FT3) (WMD = −2.29, 95% CI: −3.55 to −1.02, P=0.0004), free thyroxine (FT4) (WMD = −0.62, 95% CI: −1.05 to −0.18, P=0.0005), thyrotropin receptor antibody (TRAb) (WMD = −1.31, 95% CI: −1.63 to −0.99, P<0.00001), and thyroid peroxidase antibody (TPOAb) (WMD = −9.8, 95% CI: −16.57 to −3.03, P=0.005) in the observation group (selenium supplementation combined with antithyroid drugs) were significantly lower than those in the control group (antithyroid drugs combined with or without placebo). In addition, selenium supplementation can increase serum selenium (WMD = 33.29, 95% CI: 30.7 to 35.87, P<0.00001), selenoprotein levels (WMD = 1.3, 95% CI: 0.8 to 1.8, P<0.00001), and blood lipid levels (WMD = 32.3, 95% CI: 17.87 to 46.74, P<0.0001). It cannot be excluded that the process of selenium supplementation treatment will affect the patient’s lipid levels. Conclusion. Selenium is a trace mineral that is crucial for human health. In patients with Graves’ disease, the use of antithyroid medications along with selenium supplementation can considerably enhance thyroid function. It has the potential to drastically lower TPOAb and TRAb levels as well as FT3 and FT4 levels, which is crucial for the treatment, recovery, and prognosis of hyperthyroid patients. Further research is required to determine whether the impact of antioxidant supplementation on blood lipids will restrict the use of this medication.</description><subject>Antioxidants</subject><subject>Clinical trials</subject><subject>Drug dosages</subject><subject>Enzymes</subject><subject>Graves disease</subject><subject>Hormones</subject><subject>Hyperthyroidism</subject><subject>Immune system</subject><subject>Iodide peroxidase</subject><subject>Lipids</subject><subject>Medical research</subject><subject>Meta-analysis</subject><subject>Oxidative stress</subject><subject>Patients</subject><subject>Selenium</subject><subject>Statistical analysis</subject><subject>Supplements</subject><subject>Thyroid</subject><subject>Thyroid gland</subject><subject>Thyroid hormones</subject><subject>Thyroid-stimulating hormone</subject><subject>Thyroxine</subject><subject>Triiodothyronine</subject><issn>0269-4727</issn><issn>1365-2710</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNp9kMFKAzEURYMoWKs7PyDgUscmL5Nkxt1QaxUqLtR1SGdeMKWdGSep2p2_4e_5JU5p18KDC4_D5XIIOefsmnMpR8BAjKTMtFD8gAy4UDIBzdkhGTBQeZJq0MfkJIQFY0xpEAMymziHZQy0cbSoo2--fGXrSJ_XbbvEFdbR9s-a9jft7AeG3-8feusD2oA3tKCPGG1S1Ha5CT6ckiNnlwHP9jkkr3eTl_F9MnuaPoyLWVKC1DHRwHJdYa6EQMu1LSVwsFxYjRUozR2DMmXzTGVKO5AKwGWZRsBcznNW5mJILna9bde8rzFEs2jWXT8iGMgglb0CLnvqakeVXRNCh860nV_ZbmM4M1tfZuvL7H31-OUOf_N1ZT_9__Qfouxo_Q</recordid><startdate>20230603</startdate><enddate>20230603</enddate><creator>Song, Qi</creator><creator>Ji, Xiaoxue</creator><creator>Xie, Ying</creator><general>Hindawi</general><general>Hindawi Limited</general><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M7N</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><orcidid>https://orcid.org/0000-0002-0735-7198</orcidid></search><sort><creationdate>20230603</creationdate><title>Effects of Antioxidant Supplementation on Graves’ Disease: A Meta-Analysis</title><author>Song, Qi ; Ji, Xiaoxue ; Xie, Ying</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c257t-72097de9633ea17ac5212a13a7ed2671f02c40b86867f25622f887e2e95b90c93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antioxidants</topic><topic>Clinical trials</topic><topic>Drug dosages</topic><topic>Enzymes</topic><topic>Graves disease</topic><topic>Hormones</topic><topic>Hyperthyroidism</topic><topic>Immune system</topic><topic>Iodide peroxidase</topic><topic>Lipids</topic><topic>Medical research</topic><topic>Meta-analysis</topic><topic>Oxidative stress</topic><topic>Patients</topic><topic>Selenium</topic><topic>Statistical analysis</topic><topic>Supplements</topic><topic>Thyroid</topic><topic>Thyroid gland</topic><topic>Thyroid hormones</topic><topic>Thyroid-stimulating hormone</topic><topic>Thyroxine</topic><topic>Triiodothyronine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Song, Qi</creatorcontrib><creatorcontrib>Ji, Xiaoxue</creatorcontrib><creatorcontrib>Xie, Ying</creatorcontrib><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access Journals</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><jtitle>Journal of clinical pharmacy and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Song, Qi</au><au>Ji, Xiaoxue</au><au>Xie, Ying</au><au>Hosohata, Keiko</au><au>Keiko Hosohata</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of Antioxidant Supplementation on Graves’ Disease: A Meta-Analysis</atitle><jtitle>Journal of clinical pharmacy and therapeutics</jtitle><date>2023-06-03</date><risdate>2023</risdate><volume>2023</volume><spage>1</spage><epage>11</epage><pages>1-11</pages><issn>0269-4727</issn><eissn>1365-2710</eissn><abstract>Objective. The main objective of this study is to evaluate the clinical efficacy of antithyroid drugs combined with antioxidant supplementation represented by selenium in the treatment of Graves’ disease. Methods. Relevant randomized controlled trials (RCTs) were searched in PubMed, MEDLINE, Embase, the Cochrane Library databases, and the Chinese Medical Association. The search was conducted from the time of library construction to December 20, 2022. Three writers gradually examined, evaluated, and graded the literature and then used RevMan 5.3 to analyze the data and develop conclusions. Results. A total of seven papers were screened according to the search requirements. The results showed that free triiodothyronine (FT3) (WMD = −2.29, 95% CI: −3.55 to −1.02, P=0.0004), free thyroxine (FT4) (WMD = −0.62, 95% CI: −1.05 to −0.18, P=0.0005), thyrotropin receptor antibody (TRAb) (WMD = −1.31, 95% CI: −1.63 to −0.99, P<0.00001), and thyroid peroxidase antibody (TPOAb) (WMD = −9.8, 95% CI: −16.57 to −3.03, P=0.005) in the observation group (selenium supplementation combined with antithyroid drugs) were significantly lower than those in the control group (antithyroid drugs combined with or without placebo). In addition, selenium supplementation can increase serum selenium (WMD = 33.29, 95% CI: 30.7 to 35.87, P<0.00001), selenoprotein levels (WMD = 1.3, 95% CI: 0.8 to 1.8, P<0.00001), and blood lipid levels (WMD = 32.3, 95% CI: 17.87 to 46.74, P<0.0001). It cannot be excluded that the process of selenium supplementation treatment will affect the patient’s lipid levels. Conclusion. Selenium is a trace mineral that is crucial for human health. In patients with Graves’ disease, the use of antithyroid medications along with selenium supplementation can considerably enhance thyroid function. It has the potential to drastically lower TPOAb and TRAb levels as well as FT3 and FT4 levels, which is crucial for the treatment, recovery, and prognosis of hyperthyroid patients. Further research is required to determine whether the impact of antioxidant supplementation on blood lipids will restrict the use of this medication.</abstract><cop>Oxford</cop><pub>Hindawi</pub><doi>10.1155/2023/5587361</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-0735-7198</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-4727 |
| ispartof | Journal of clinical pharmacy and therapeutics, 2023-06, Vol.2023, p.1-11 |
| issn | 0269-4727 1365-2710 |
| language | eng |
| recordid | cdi_proquest_journals_2824555815 |
| source | ProQuest Central (Alumni Edition); Wiley Online Library Open Access; ProQuest Central UK/Ireland; Alma/SFX Local Collection; ProQuest Central |
| subjects | Antioxidants Clinical trials Drug dosages Enzymes Graves disease Hormones Hyperthyroidism Immune system Iodide peroxidase Lipids Medical research Meta-analysis Oxidative stress Patients Selenium Statistical analysis Supplements Thyroid Thyroid gland Thyroid hormones Thyroid-stimulating hormone Thyroxine Triiodothyronine |
| title | Effects of Antioxidant Supplementation on Graves’ Disease: A Meta-Analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T12%3A28%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20Antioxidant%20Supplementation%20on%20Graves%E2%80%99%20Disease:%20A%20Meta-Analysis&rft.jtitle=Journal%20of%20clinical%20pharmacy%20and%20therapeutics&rft.au=Song,%20Qi&rft.date=2023-06-03&rft.volume=2023&rft.spage=1&rft.epage=11&rft.pages=1-11&rft.issn=0269-4727&rft.eissn=1365-2710&rft_id=info:doi/10.1155/2023/5587361&rft_dat=%3Cproquest_cross%3E2824555815%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2824555815&rft_id=info:pmid/&rfr_iscdi=true |